BioSpace News Archive

Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis

Mechelen, Belgium; 10 July 2021, 11.10 CET; Galapagos NV announced new post-hoc analyses from the Phase 3 SELECTION program, supporting the activity and tolerability of filgotinib, a once-daily, oral JAK1 preferential inhibitor, under investigation for the treatment of patients with moderately to severely active ulcerative colitis.

July 10, 2021
·
9 min read
Bio NC

BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline

BioCryst Pharmaceuticals, Inc. announced that hereditary angioedema patients who were randomized to receive 150 mg of oral, once-daily ORLADEYO® at the start of the APeX-2 trial had an 80 percent average reduction in their mean attack rate per month during weeks 25-96 of the trial, compared to baseline.

July 10, 2021
·
9 min read
Drug Development

New Data from the Phase 3 HELP Study™ Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology Hybrid Congress

Takeda Pharmaceutical Company Limited announced results from two final analyses from the Phase 3 HELP Study™ Open-label Extension, which evaluated the long-term safety and efficacy of TAKHZYRO® 300 mg every two weeks for up to 2.5 years.

July 10, 2021
·
17 min read